[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes
Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.
Enhanced immune #evasion of #SARS-CoV-2 variants #KP311 and #XEC through N-terminal domain #mutations
Source: Lancet Infectious Diseases, Correspondence, {Excerpt} KP.3, a subvariant of JN.1, has rapidly emerged as the dominant strain of SARS-CoV-2 in several countries, and has been designated as a Variant Under Monitoring. Previous studies indicate that the unique Q493E substitution in KP.3 Spike glycoprotein enhances its receptor ACE2-binding affinity and immune…
Source: Lancet Infectious Diseases, Correspondence, {Excerpt} KP.3, a subvariant of JN.1, has rapidly emerged as the dominant strain of SARS-CoV-2 in several countries, and has been designated as a…
Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between…
Robust antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against a broad range of SARS-CoV-2 Omicron subvariants including JN.1, KP.3.1.1 and XEC
In the case of the JN.1 monovalent mRNA vaccine, we showed that the 50% neutralization titer against XBB.1.5 is greater than that against ancestral B.1.1. This implies that immune imprinting has shifted from pre-Omicron to biased toward Omicron.
#mRNA #Vaccines #XEC #JN1 #KP311
https://www.biorxiv.org/content/10.1101/2024.11.20.624471v1
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
#Impact of #JN1 #booster #vaccination on #neutralisation of #SARS-CoV-2 variants #KP311 and #XEC
Source: BioRxIV, {Excerpt} Conclusion Collectively, we found that the XEC S protein retains the ability to efficiently engage ACE2 and drive cell entry, although entry into Calu-3 lung cells was reduced. Both KP.3.1.1pp and XECpp were generally less well neutralised compared to JN.1pp, indicating elevated immune evasion. Importantly, JN.1-booster vaccination significantly…
Source: BioRxIV, {Excerpt} Conclusion Collectively, we found that the XEC S protein retains the ability to efficiently engage ACE2 and drive cell entry, although entry into Calu-3 lung cells was re…
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
Le dernier #variant d’ #Omicron majoritaire en #France mais peu virulent https://www.lemonde.fr/sciences/article/2024/08/30/le-dernier-variant-d-omicron-majoritaire-en-france-mais-peu-virulent_6299007_1650684.html
Depuis son apparition fin 2019, le virus du #Covid19 a muté régulièrement avec un dernier sous-variant, le #KP311, porteur de trois mutations qui le rendent plus contagieux.
[Correspondence] Virological #characteristics of the #SARS-CoV-2 #KP311 #variant https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00505-X/fulltext?rss=yes
SARS-CoV-2 #JN1 variant (#BA28611), arising from BA.2.86.1 with spike protein (S) substitution S:L455S, outcompeted previously predominant #XBB lineages by beginning of 2024. Subsequently, JN.1 subvariants including #KP2 (JN.1.11.1.2) & #KP3 (JN.1.11.1.3), which acquired additional S substitutions (eg, S:R346T, S:F456L, and S:Q493E) have emerged concurrently (appendix pp 19–20).2
#Pemivibart is less active against recent #SARS-CoV-2 #JN1 #sublineages http://biorxiv.org/cgi/content/short/2024.08.12.607496v1?rss=1
Pemivibart neutralized both JN.1 and #KP2 in vitro with comparable activity, whereas its potency was decreased slightly against #LB1, #KP23, and #KP3 but substantially against #KP311. Critically, the 50% inhibitory concentration of pemivibart against KP.3.1.1 was ~6 g/mL, or ~32.7 fold higher than that of JN.1.
Giuseppe Michieli
Zoomers of the Sunshine Coast 🇨🇦